Bao Xiao Hong, Naomoto Yoshio, Hao Hui Fang, Watanabe Nobuyuki, Sakurama Kazufumi, Noma Kazuhiro, Motoki Takayuki, Tomono Yasuko, Fukazawa Takuya, Shirakawa Yasuhiro, Yamatsuji Tomoki, Matsuoka Junji, Takaoka Munenori
Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
Oncol Lett. 2010 Jan;1(1):195-201. doi: 10.3892/ol_00000036. Epub 2010 Jan 1.
The type I insulin-like growth factor receptor (IGF-IR) and its associated signaling system play a significant role in tumorigenesis, tumor survival and progression, and cancer therapeutic resistance, and thus has provoked great interest as a promising target for cancer treatment. In this report we present the role of IGF-IR in gastrointestinal carcinomas whose pathology has been identified as tightly correlated with an abnormal expression and activation of IGF-IR. Reported data from experimental studies suggest the feasibility of targeted IGF-IR therapy in gastrointestinal carcinomas. Many types of inhibitors against IGF-IR have been developed. Inhibitors with anti-IGF-IR monoclonal antibodies and tyrosine kinase inhibitors currently undergoing preclinical and clinical evolution are also reviewed.
I型胰岛素样生长因子受体（IGF-IR）及其相关信号系统在肿瘤发生、肿瘤存活与进展以及癌症治疗耐药性中发挥着重要作用，因此作为一个有前景的癌症治疗靶点引发了极大关注。在本报告中，我们阐述了IGF-IR在胃肠道癌中的作用，其病理学已被确定与IGF-IR的异常表达和激活密切相关。来自实验研究的报道数据表明在胃肠道癌中进行靶向IGF-IR治疗具有可行性。已经研发出多种针对IGF-IR的抑制剂。本文还综述了目前正在进行临床前和临床研究的抗IGF-IR单克隆抗体和酪氨酸激酶抑制剂类抑制剂。
